BR112014031278B1 - uso de lipossomos vazios, mistura de lipossomos vazios, bicamadas lipídicas ou monocamadas lipídicas, bem como mistura de lipossomos vazios - Google Patents

uso de lipossomos vazios, mistura de lipossomos vazios, bicamadas lipídicas ou monocamadas lipídicas, bem como mistura de lipossomos vazios Download PDF

Info

Publication number
BR112014031278B1
BR112014031278B1 BR112014031278-8A BR112014031278A BR112014031278B1 BR 112014031278 B1 BR112014031278 B1 BR 112014031278B1 BR 112014031278 A BR112014031278 A BR 112014031278A BR 112014031278 B1 BR112014031278 B1 BR 112014031278B1
Authority
BR
Brazil
Prior art keywords
liposomes
sphingomyelin
empty liposomes
cholesterol
mixture
Prior art date
Application number
BR112014031278-8A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014031278A2 (pt
Inventor
Eduard Babiychuk
Annette Draeger
Original Assignee
Universitaet Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Bern filed Critical Universitaet Bern
Publication of BR112014031278A2 publication Critical patent/BR112014031278A2/pt
Publication of BR112014031278B1 publication Critical patent/BR112014031278B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
BR112014031278-8A 2012-06-14 2013-06-13 uso de lipossomos vazios, mistura de lipossomos vazios, bicamadas lipídicas ou monocamadas lipídicas, bem como mistura de lipossomos vazios BR112014031278B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12171924 2012-06-14
EP12171924.9 2012-06-14
EP13153039.6 2013-01-29
EP13153039 2013-01-29
PCT/EP2013/062207 WO2013186286A1 (en) 2012-06-14 2013-06-13 Tailored liposomes for the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
BR112014031278A2 BR112014031278A2 (pt) 2017-06-27
BR112014031278B1 true BR112014031278B1 (pt) 2020-12-01

Family

ID=48703423

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014031278-8A BR112014031278B1 (pt) 2012-06-14 2013-06-13 uso de lipossomos vazios, mistura de lipossomos vazios, bicamadas lipídicas ou monocamadas lipídicas, bem como mistura de lipossomos vazios

Country Status (19)

Country Link
US (4) US10744089B2 (https=)
EP (2) EP2861214B1 (https=)
JP (2) JP6382801B2 (https=)
CN (2) CN104602672B (https=)
AU (2) AU2013276565B2 (https=)
BR (1) BR112014031278B1 (https=)
CA (1) CA2875470C (https=)
CY (1) CY1123337T1 (https=)
DK (1) DK2861214T3 (https=)
ES (1) ES2821502T3 (https=)
HR (1) HRP20201761T1 (https=)
HU (1) HUE051761T2 (https=)
LT (1) LT2861214T (https=)
PL (1) PL2861214T3 (https=)
RS (1) RS60951B1 (https=)
RU (1) RU2672106C2 (https=)
SI (1) SI2861214T1 (https=)
SM (1) SMT202000584T1 (https=)
WO (1) WO2013186286A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2861214T (lt) * 2012-06-14 2020-12-28 Universität Bern Specialiai pritaikytos liposomos, skirtos bakterinių infekcijų gydymui
US20170000875A1 (en) 2013-12-02 2017-01-05 Arytha Biosciences, Llc Toxoid preparation and uses thereof
US10739353B2 (en) * 2014-12-31 2020-08-11 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
EP3397245A4 (en) * 2015-12-28 2019-08-28 MB Biotech Ltd. LIPOSOME FOR THE TREATMENT OF AUTOIMMUNE DISEASES
WO2017177073A1 (en) * 2016-04-07 2017-10-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use
PL3471732T3 (pl) 2016-06-16 2020-10-19 Combioxin Sa Liposomy do leczenia infekcji wirusowych
CN110636839B (zh) * 2017-03-02 2023-06-27 康柏辛股份有限公司 抑制生物膜形成的脂质体
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
AU2019254515B9 (en) * 2018-04-17 2025-06-26 Combioxin Sa Treatment of pneumonia
CN111971068B (zh) * 2018-04-20 2025-09-02 康柏辛股份有限公司 败血症和败血性休克的治疗
CN111214439B (zh) * 2018-11-23 2023-02-10 复旦大学 一种具有细菌成孔毒素吸附性能的纳米药物系统及其用途
CN115768499A (zh) 2020-01-20 2023-03-07 阿瑞萨生物科技有限责任公司 含有细胞膜的装置及其用途
WO2022026170A1 (en) * 2020-07-31 2022-02-03 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
CN115054577B (zh) * 2022-05-17 2024-06-21 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 纳米解毒剂及其在中和mrsa穿孔毒素的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641247A (en) 1970-12-14 1972-02-08 Stanley Drug Products Inc Methods of treating bacterial infections
AU6428890A (en) * 1989-09-12 1991-04-18 Regents Of The University Of California, The Therapeutic peptides and proteins
NL9000207A (https=) * 1990-01-29 1991-08-16 Duphar Int Res
AU2583892A (en) 1991-09-11 1993-04-05 Pitman-Moore, Inc. Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US8110217B2 (en) * 2001-08-13 2012-02-07 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
ES2387886T3 (es) * 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Composiciones que transportan lípidos con una mejor estabilidad sanguínea
CA2368656A1 (en) * 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
IL163733A0 (en) 2002-03-08 2005-12-18 Eisai Co Ltd Presynaptic protein p120
EP1531828A4 (en) * 2002-05-23 2005-11-02 Activbiotics Inc METHODS OF TREATING BACTERIAL INFECTIONS AND ASSOCIATED DISEASES
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
US20060198882A1 (en) * 2003-03-21 2006-09-07 Yechezkel Barenholz Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
LT3173073T (lt) 2004-05-03 2025-01-10 Ipsen Biopharm Ltd. Liposomos, skirtos vaistų pristatymui
US20090285878A1 (en) * 2004-11-05 2009-11-19 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
JPWO2007018275A1 (ja) 2005-08-11 2009-02-19 独立行政法人産業技術総合研究所 ローリングモデルに基づく、送達媒体の設計
CN1939340A (zh) * 2005-09-29 2007-04-04 中国人民解放军军事医学科学院毒物药物研究所 脂质体制剂
WO2008039989A2 (en) * 2006-09-28 2008-04-03 Transave, Inc. Formulations of dnase and methods of use thereof
JP2010509355A (ja) * 2006-11-06 2010-03-25 ジャイナ ファーマシューティカルズ，インコーポレーテッド グッグルリン脂質の方法および組成物
CN1994279A (zh) * 2006-12-31 2007-07-11 西安力邦医药科技有限责任公司 注射用盐酸伊立替康脂质体的制备方法
US8906855B2 (en) 2007-12-22 2014-12-09 Vivacelle Bio, Inc. Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
CN101623262B (zh) * 2009-08-24 2011-02-02 海南美大制药有限公司 一种五水头孢唑啉钠前体脂质体制剂
WO2011160110A1 (en) * 2010-06-19 2011-12-22 Western University Of Health Sciences Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
SG187770A1 (en) * 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
CN102327220B (zh) * 2011-07-14 2012-09-26 海南灵康制药有限公司 一种氯雷他定脂质体固体制剂
LT2861214T (lt) 2012-06-14 2020-12-28 Universität Bern Specialiai pritaikytos liposomos, skirtos bakterinių infekcijų gydymui
WO2017222912A1 (en) 2016-06-20 2017-12-28 Vivacelle Bio, Inc. Compositions and methods for reducing reperfusion injury
CN110636839B (zh) 2017-03-02 2023-06-27 康柏辛股份有限公司 抑制生物膜形成的脂质体
AU2019254515B9 (en) 2018-04-17 2025-06-26 Combioxin Sa Treatment of pneumonia

Also Published As

Publication number Publication date
CY1123337T1 (el) 2021-12-31
CA2875470C (en) 2021-01-12
EP2861214B1 (en) 2020-08-05
AU2019201776B2 (en) 2020-11-12
RS60951B1 (sr) 2020-11-30
BR112014031278A2 (pt) 2017-06-27
SI2861214T1 (sl) 2021-01-29
US12599558B2 (en) 2026-04-14
CN104602672B (zh) 2018-12-25
US10744089B2 (en) 2020-08-18
JP2015519383A (ja) 2015-07-09
CN109549925A (zh) 2019-04-02
CN109549925B (zh) 2022-06-17
WO2013186286A1 (en) 2013-12-19
RU2672106C2 (ru) 2018-11-12
PL2861214T3 (pl) 2021-02-08
DK2861214T3 (da) 2020-10-12
HRP20201761T1 (hr) 2020-12-25
CA2875470A1 (en) 2013-12-19
US20150157570A1 (en) 2015-06-11
JP2018184470A (ja) 2018-11-22
US20220087934A1 (en) 2022-03-24
US20230031648A1 (en) 2023-02-02
US20200345639A1 (en) 2020-11-05
ES2821502T3 (es) 2021-04-26
JP6382801B2 (ja) 2018-08-29
EP3782606A1 (en) 2021-02-24
HUE051761T2 (hu) 2021-03-29
LT2861214T (lt) 2020-12-28
EP2861214A1 (en) 2015-04-22
AU2013276565B2 (en) 2018-12-20
HK1210018A1 (en) 2016-04-15
CN104602672A (zh) 2015-05-06
SMT202000584T1 (it) 2020-11-10
RU2018138012A (ru) 2019-03-21
RU2014148284A (ru) 2016-08-10
AU2019201776A1 (en) 2019-04-04
AU2013276565A1 (en) 2014-12-18
JP6656321B2 (ja) 2020-03-04

Similar Documents

Publication Publication Date Title
US12599558B2 (en) Tailored liposomes for the treatment of bacterial infections
AU2019262189B2 (en) Carotenoid compositions and uses thereof
US10632070B2 (en) Hydrogel toxin-absorbing or binding nanoparticles
US10376508B2 (en) Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
RU2780026C2 (ru) Специально разработанные липосомы для лечения бактериальных инфекций
HK40046902A (en) Tailored liposomes for the treatment of bacterial infections
HK1210018B (zh) 用於治疗细菌感染的定制脂质体
US20210007985A1 (en) Liposomal anti-infective formulations to inhibit non-tuberculous mycobacteria (ntm) microaggregate formation and establishment of ntm biofilm
Solleti Formulation and efficacy of liposome-encapsulated azithromycin for pulmonary infection due to Pseudomonias aeruginosa
HK1240086A1 (en) Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/06/2013, OBSERVADAS AS CONDICOES LEGAIS.